Skip to content

A prospective randomized controlled trial of ropivacaine hydrochloride empirical formula for local infiltration block in the treatment of acute pain after arthroscopic anterior cruciate ligament reconstruction

A prospective randomized controlled trial of ropivacaine hydrochloride empirical formula for local infiltration block in the treatment of acute pain after arthroscopic anterior cruciate ligament reconstruction

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070305
Enrollment
Unknown
Registered
2023-04-08
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rupture of the anterior cruciate ligament

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective arthroscopic anterior cruciate ligament reconstruction in sports medicine Department of our hospital; 2. Age: 18-65 years old; 3. ASA I to II; 4. 18 kg/m^2 <= BMI <= 25 kg/m^2; 5. No communication barriers, able to understand the study process and the use of pain scales; 6. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergies to drugs related to the study; 2. History of chronic pain, long-term use of analgesic drugs (equivalent to >= 10mg oxycodone daily), alcohol abuse, and gastrointestinal bleeding or perforation after NSaids; 3. Patients with ischemic heart disease, peripheral arterial or cerebrovascular disease, or patients with pulmonary heart disease, active digestive ulcer or gastrointestinal bleeding, or patients with inflammatory bowel disease; 4. Patients taking monoamine oxidase inhibitors or within 2 weeks after discontinuation; 5. Participated in other clinical studies within three months.

Design outcomes

Primary

MeasureTime frame
Resting visual simulation score and active visual simulation score;

Secondary

MeasureTime frame
Vital signs;Drug-related adverse reactions;Surgical complications;Overall patient quality of recovery;Additional analgesic drug use;Plasma concentration of ropivacaine hydrochloride;

Countries

China

Contacts

Public ContactChen Gang

West China Hospital, Sichuan University

drchengang@foxmail.com+86 18980606707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026